Krsnaa Diagnostics FY26 Profit Rises 31% to Rs 1,014 Million

Consolidated revenue increased 8% YoY to Rs 7,728 million, with EBITDA margins reaching 28%.

Reader Takeaway: Strong profit growth and successful ADB funding for expansion are balanced by the operational risks of large-scale PPP rollouts.

What just happened

Krsnaa Diagnostics Limited announced its financial results for FY 2025-26, highlighting a 31% surge in consolidated Profit After Tax (PAT) to Rs 1,014 million. The company reported a consolidated revenue of Rs 7,728 million, an 8% increase compared to the previous year. Operational efficiency drove EBITDA to Rs 2,149 million, reflecting a margin improvement to 28%.

Why this matters

The financial results signal successful scaling of the company’s diagnostic footprint. Krsnaa processed over 59 million tests during the year, serving 20 million patients. A key development was the successful allotment of Rs 4,300 million in NCDs to the Asian Development Bank, specifically for project implementation including a major contract in Rajasthan. The company’s retail segment, while currently small, has grown six-fold and now accounts for 8% of total revenue.

Corporate Actions

The Board of Directors has recommended a final dividend of Rs 2.00 per share, which will be subject to approval at the upcoming Annual General Meeting on September 28, 2026. Governance shifts also occurred, with the retirement of several Independent Directors and the appointment of new members, including Raju Venkatraman and Lilian Jessie Paul.

What to track next

Investors should monitor the execution of the Rajasthan project, which involves establishing 27 mother labs and 800 collection centres. Continued growth in the retail segment and the stability of the 75% bid-win ratio in government tenders will be critical to sustaining margins in the coming quarters.